Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

Abstract	Tallimustine binds to the minor groove of DNA where it alkylates the N3 position of adenine and may interfere with gene transcription. We conducted a phase II trial of Tallimustine given at a dose of 750 micrograms/m2 intravenously every 4 weeks in patients with small cell lung cancer progressing or relapsing following cisplatin or carboplatin-based chemotherapy. We treated 14 eligible patients with a performance status 0, 1 or 2, bi-dimensionally measurable disease and adequate end-organ function. The main toxicity was neutropenia with a median granulocyte count of 0.1 x 10(9) per liter (range 0-3.9) and four patients (27%) developing febrile neutropenia. In addition, most patients (93%) experienced lethargy. No objective responses were seen. A mixed response was seen in one patient and three others had stable disease for a median of 3.7 months. We conclude that Tallimustine is an ineffective agent in previously treated small cell lung cancer.
Authors	J Viallet, D Stewart, F Shepherd, J Ayoub, Y Cormier, N DiPietro, W Steward
Journal	Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 15 Issue 3 Pg. 367-73 (Nov 1996) ISSN: 0169-5002 [Print] Ireland
PMID	8959681 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Antineoplastic Agents Distamycins Nitrogen Mustard Compounds tallimustine
Topics	Aged Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use) Canada Carcinoma, Small Cell (drug therapy, mortality, pathology) Disease Progression Distamycins (administration & dosage, adverse effects, therapeutic use) Dose-Response Relationship, Drug Female Follow-Up Studies Humans Infusions, Intravenous Leukocyte Count Lung Neoplasms (drug therapy, mortality, pathology) Male Middle Aged Neoplasm Recurrence, Local Neutropenia (blood, chemically induced) Nitrogen Mustard Compounds (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!